+

WO2008147864A3 - Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions - Google Patents

Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions Download PDF

Info

Publication number
WO2008147864A3
WO2008147864A3 PCT/US2008/064498 US2008064498W WO2008147864A3 WO 2008147864 A3 WO2008147864 A3 WO 2008147864A3 US 2008064498 W US2008064498 W US 2008064498W WO 2008147864 A3 WO2008147864 A3 WO 2008147864A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
sodium channel
mediated diseases
methods
piperazine compounds
Prior art date
Application number
PCT/US2008/064498
Other languages
French (fr)
Other versions
WO2008147864A2 (en
Inventor
Robert Fraser
Jianmin Fu
Rajender Kamboj
Vishnumurthy Kodumuru
Kashinath Sadalapure
Original Assignee
Xenon Pharmaceuticals Inc
Robert Fraser
Jianmin Fu
Rajender Kamboj
Vishnumurthy Kodumuru
Kashinath Sadalapure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Robert Fraser, Jianmin Fu, Rajender Kamboj, Vishnumurthy Kodumuru, Kashinath Sadalapure filed Critical Xenon Pharmaceuticals Inc
Publication of WO2008147864A2 publication Critical patent/WO2008147864A2/en
Publication of WO2008147864A3 publication Critical patent/WO2008147864A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to piperazine compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
PCT/US2008/064498 2007-05-22 2008-05-22 Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions WO2008147864A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93958607P 2007-05-22 2007-05-22
US60/939,586 2007-05-22

Publications (2)

Publication Number Publication Date
WO2008147864A2 WO2008147864A2 (en) 2008-12-04
WO2008147864A3 true WO2008147864A3 (en) 2009-07-09

Family

ID=40075732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064498 WO2008147864A2 (en) 2007-05-22 2008-05-22 Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions

Country Status (1)

Country Link
WO (1) WO2008147864A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398516A (en) * 2009-02-20 2015-03-11 阿斯利康(瑞典)有限公司 Cyclopropyl amide derivatives targeting the histamine h3 receptor
CN110204511B (en) * 2019-06-27 2023-04-11 南京神奇科技开发有限公司 Thymol amino alcohol and preparation method and application thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478044T1 (en) 2005-09-16 2010-09-15 Arrow Therapeutics Ltd BIPHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS C
PL2142529T3 (en) 2007-04-27 2014-06-30 Purdue Pharma Lp Trpv1 antagonists and uses thereof
TWI432422B (en) 2007-08-22 2014-04-01 Astrazeneca Ab Cyclopropyl guanamine derivative
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
SG182732A1 (en) 2010-02-18 2012-08-30 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
US8999974B2 (en) 2010-08-09 2015-04-07 Raqualia Pharma Inc. Acyl piperazine derivatives as TTX-S blockers
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
MX354015B (en) 2011-06-22 2018-02-08 Shionogi & Co TRPV1 ANTAGONISTS THAT INCLUDE SUBSTITUTES DIHIDROXI AND ITS USES.
EP2729149A4 (en) * 2011-07-06 2015-01-07 Glaxo Group Ltd Voltage-gated sodium channel blockers
RU2014110401A (en) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. KIDNEY EXTERNAL KIDNEY KIDNEY CHANNEL INHIBITORS
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771004B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (en) 2012-07-26 2015-03-18 Merck Sharp & Dohme INHIBITORS OF THE EXTERNAL RENAL MEDULAR POTASSIUM CHANNEL
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2956142B1 (en) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
KR102093409B1 (en) * 2019-10-23 2020-03-25 고려대학교 산학협력단 Anti-fungal Composition Comprising Carbazole Compound
CN111662288B (en) * 2020-06-23 2022-06-14 徐州医科大学 A small molecule compound that inhibits the activity of AKT and STAT3 and its application
US20240300934A1 (en) * 2021-07-07 2024-09-12 Trustees Of Tufts College Compounds for modulating mycobacterium tuberculosis response

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
WO1996037489A1 (en) * 1995-05-25 1996-11-28 Fujisawa Pharmaceutical Co., Ltd. 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
WO1997043259A1 (en) * 1996-05-10 1997-11-20 Monash University Arylalkylpiperazine compounds as antioxidants
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
WO2004032933A1 (en) * 2002-10-11 2004-04-22 Kowa Co., Ltd. Method for treatment of cancer
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2007109324A2 (en) * 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
WO1996037489A1 (en) * 1995-05-25 1996-11-28 Fujisawa Pharmaceutical Co., Ltd. 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
WO1997043259A1 (en) * 1996-05-10 1997-11-20 Monash University Arylalkylpiperazine compounds as antioxidants
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
WO2004032933A1 (en) * 2002-10-11 2004-04-22 Kowa Co., Ltd. Method for treatment of cancer
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2007109324A2 (en) * 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARCELLER E ET AL: "(Pyridylcyanomethyl)piperazines as Orally Active PAF Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON.; US, vol. 35, no. 22, 30 October 1992 (1992-10-30), pages 4118 - 4134, XP002008877, ISSN: 0022-2623 *
CLARE J J ET AL: "Voltage-Gated Sodium Channels as Therapeutic Targets", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 5, no. 11, 1 November 2000 (2000-11-01), pages 506 - 520, XP002985023, ISSN: 1359-6446 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398516A (en) * 2009-02-20 2015-03-11 阿斯利康(瑞典)有限公司 Cyclopropyl amide derivatives targeting the histamine h3 receptor
CN110204511B (en) * 2019-06-27 2023-04-11 南京神奇科技开发有限公司 Thymol amino alcohol and preparation method and application thereof

Also Published As

Publication number Publication date
WO2008147864A2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2009008338A (en) Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions.
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2008121861A3 (en) Pyrazole and pyrrole compounds useful in treating iron disorders
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200734311A (en) New compounds
WO2008149382A8 (en) Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008115999A8 (en) Biaryl and biheteroaryl compounds useful in treating iron disorders
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
MY167135A (en) Fused heterocyclic derivatives and methods of use
TN2012000171A1 (en) Synthetic methods for spiro-oxindole compounds
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MY157017A (en) Sulfonamide derivatives
WO2009047798A3 (en) Acetamide derivatives as glucokinase activators, their process and medicinal applications
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
UA85471C2 (en) Use of oxycodone for treating visceral pain
MX2009003874A (en) Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents.
SI2054418T1 (en) Dihydrothieno pyrimidines as akt protein kinase inhibitors
WO2011028044A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011028043A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08769604

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08769604

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载